MBRX Moleculin Biotech Inc

Price (delayed)

$0.5279

Market cap

$10.28M

P/E Ratio

0.06

Dividend/share

N/A

EPS

$8.64

Enterprise value

$3.17M

?
Relative Growth: Rel. Growth: 25
Relative Strength: Rel. Strength: 0
Relative Valuation: Rel. Valuation: 79
Relative Profitability: Rel. Profitability: 5

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation ...

Highlights
The EPS has surged by 146% since the previous quarter and by 108% year-on-year
MBRX's debt is down by 50% year-on-year and by 21% since the previous quarter
MBRX's quick ratio is down by 40% since the previous quarter and by 19% year-on-year
The company's equity fell by 24% QoQ

Key stats

What are the main financial stats of MBRX

MBRX stock price

How has the Moleculin Biotech stock price performed over time
Intraday
-6.57%
1 week
-28.66%
1 month
-10.98%
1 year
-95.09%
YTD
-84.05%
QTD
-81.08%

Financial performance

How have Moleculin Biotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.87M
Net income
-$30.33M
Gross margin
N/A
Net margin
N/A
MBRX's net income is up by 25% since the previous quarter and by 19% year-on-year
MBRX's operating income is down by 13% YoY and by 7% from the previous quarter

Price vs fundamentals

How does MBRX's price correlate with its fundamentals

Growth

What is Moleculin Biotech's growth rate over time

Valuation

What is Moleculin Biotech stock price valuation
P/E
0.06
P/B
0.24
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 146% since the previous quarter and by 108% year-on-year
MBRX's price to book (P/B) is 99% lower than its 5-year quarterly average of 18.7
The company's equity fell by 24% QoQ

Efficiency

How efficient is Moleculin Biotech business performance
The company's return on equity rose by 32% YoY
Moleculin Biotech's return on assets has increased by 23% QoQ and by 17% YoY

Dividends

What is MBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MBRX.

Financial health

How did Moleculin Biotech financials performed over time
Moleculin Biotech's total assets is 122% higher than its total liabilities
The total liabilities has dropped by 67% year-on-year but it has increased by 16% since the previous quarter
MBRX's quick ratio is down by 40% since the previous quarter and by 19% year-on-year
MBRX's debt is 99% smaller than its equity
The debt to equity has soared by 125% YoY
MBRX's debt is down by 50% year-on-year and by 21% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.